INC.;EMORY UNIVERSITY;DANA-FARBER CANCER INSTITUTE;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
FREEMAN, GORDON J.,AHMED, RAFI,JONES, TIMOTHY D.,CARR, FRANCIS J.,GREGSON, JAMES P.
申请号：
CA2738252
公开号：
CA2738252C
申请日:
2009.09.25
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present inventionis based, in part, on the identificationof novel human anti-PD-1, PD-L1,and PD-L2 antibodies. Accordingly,the invention relates to compositionsand methods for diagnosing, prognosing,and treating conditions thatwould benefit from modulating PD-1,PD-L1, and/or PD-L2 activity (e.g.,persistent infectious diseases, autoimmunediseases, asthma, transplant rejection,inflammatory disorders andtumors) using the novel humananti-PD-1, PD-L1, and PD-L2 antibodiesdescribed herein.
